MEETINGS - On Strategies in the Non/minimally Invasive Diagnostic Market (UK) December 1999:
This article was originally published in Clinica
Executive Summary
A meeting on Strategies in the Non/Minimally Invasive Diagnostic Market will take place in London on December 6-7. It will cover European and global regulatory issues, strategic partnering, cost effectiveness of centralised laboratory testing, differing approaches to cancer diagnostics and risk stratification and diagnostic tools. Two workshops will also take place on Dec 8 - Strategic Planning for a Successful In Vitro Diagnostics Portfolio and Regulatory and Reimbursement Strategies in the Diagnostics Industry. Further details may be obtained from SMi in the UK. Tel: +44 20 7252 2222. Fax: +44 20 7252 2272.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.